To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
Completed · Phase 1 · Has a placebo group
Conditions studied: Solid Tumours
In brief
Study to assess the effect of Selumetinib \[AZD6244; ARRY-142886\] \[Hyd-Sulfate\]), on QTc interval in healthy male volunteers.
Key facts
- Study ID
- NCT02056392
- Run by
- AstraZeneca
- People needed
- 54
- Starts
- 2014-03-01
- Expected to finish
- 2014-08-01
- Last updated by the study team
- 2015-11-09
Who can join
Age: 18 and older, up to 45. Sex: male. Healthy volunteers: accepted.
Where it is running
- Research Site — Overland Park, Kansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.